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Abstract
Background: Linc00152 has been identified highly associated with the tumorigenesis and development of gastric
cancer, however, the detailed mechanism of Linc00152 involved still remains unclear.
Methods: RT-PCR and western blot were used to detect the expression of Linc00152 and EGFR. The CCK8 and EDU
assay was employed to measure cell proliferation while xenotransplantation technology was applied in BALB/C
nude mice. The interaction between lncRNA and target protein was investigated by RNA pull-down and RNA
immunoprecipitation assay.
Results: In this study, we first confirmed the upregulation of cytoplasmic expressed Linc00152 in 72 pair tissues of
gastric patients. A suppression of cell proliferation and tumor growth was obtained in MGC803 and HGC-27 cells
treated with Linc00152 shRNA. RNA pull-down and RIP assay revealed that Linc00152 could directly bind with EGFR
which caused an activation of PI3K/AKT signaling.
Conclusion: We first found that Linc00152 could promote tumor growth through EGFR-mediated PI3K/AKT
pathway which may serve as potential targets for therapy in the future.
Keywords: LncRNA, Xenograft transplantation, RNA pull-down, EGFR, PI3K
Background
Gastric cancer (GC) is one of the most common malignant
tumors and the second leading cause of cancer-related
mortality worldwide [1, 2]. Despite recent improvements
in surgery and chemotherapy, gastric cancer remains a very
high morbidity and mortality [3, 4]. Therefore, the further
investigation of potential mechanism, prognostic bio-
markers or therapeutic targets of gastric cancer is essential
for the development of useful indicators that aid novel
effective therapies for gastric cancer [1, 5, 6].
With the development of whole-genome sequencing
technology, it was determined that less than 2 % of the
mammalian genome is in protein-encoded regions and
the remainder is in noncoding RNAs (ncRNAs) [7].
Among them are long noncoding RNAs (lncRNAs) with
the transcripts of greater than 200 nucleotides with no
or little protein coding function [8]. Recent studies have
identified multiple functional effects of lncRNAs involving
in multiple progression of human cancers including
regulating gene expression through modulation of chro-
matin remodeling, controlling of gene transcription, post-
transcriptional mRNA processing, protein function or
localization and intercellular signaling [9–11]. Further-
more, Researchers also identified that several lncRNAs
could be modified epigenetically including methylation,
ubiquitination, miRNA-induced regulation though a
network [12, 13].
In this study, we mainly focused on the reported
lncRNA entitled Linc00152. It has been reported that
Linc00152 was participated in cell cycle arrest, apoptosis,
epithelial to mesenchymal transition (EMT), cell migra-
tion and invasion in gastric cancer [14]. Further exploring
found that Linc00152 could also act as a circulating
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biomarker for the diagnosis of gastric cancer [15]. All the
identified results revealed that Linc00152 played a crucial
role in the pathogenesis of gastric cancers; however, the
detailed mechanism of Linc00152 involved as well as the
target protein or signaling still remain unclear.
In the present study, we found that Linc00152 was
up-regulated in GC tissues than that in corresponding
non-tumor tissues. We also confirmed that Linc00152
could regulate cell growth both in vitro and in vivo.
In addition, we demonstrated that cytoplasmic
Linc00152 could directly bind with EGFR which
caused a constitutive expression and activation of
EGFR and EGFR signaling pathway.
Methods
Clinical samples and cell cultures
The clinical data was obtained from 72 cases of patients
who underwent gastric cancer radical resection surgery
during January 2010 to December 2014 at Yixing People
Hospital Affiliated to Jiangsu University (Wuxi, China).
No patient had the history of exposure to either
radiotherapy or chemotherapy before the surgery, and no
other co-occurrence cancers was diagnosed. This study
was approved by the Ethical Committee of Jiangsu Univer-
sity, and every patient had written informed consent.
The human gastric cancer cell lines used in this study
were obtained from the American Type Culture Collec-
tion (ATCC) (Manassas, VA, USA). All the cell lines were
maintained in an atmosphere of 5 % CO2 and grown in
suitable medium (Thermo, Beijing, China) supplemented
with 10 % fetal bovine serum (Thermo, Beijing, China).
Cell lines authentication was performed by STR profiling
before initiation of this study.
Quantitative real time polymerase chain reaction (qRT-PCR)
Quantitative real time polymerase chain reaction (qRT-
PCR) was performed to determine the expression levels
of Linc00152 and other related mRNAs. Total RNAs
were extracted from frozen tissues and cell lines using
TRIzol reagent as described by the manufacturer’s proto-
col (Invitrogen Life Technologies Co, CA, USA). GAPDH
was used as an internal control. RT-PCR was performed
Fig. 1 Cytoplasm located Linc00152 was increased in gastric cancer. a Relative expression level of Linc00152 in 72 pairs tissues obtained from
gastric cancer patients. Data was presented with mean ± SEM. 18S was used as internal control. b Different expression of Linc00152 in gastric
cancer cell lines. c The subcellular location and intensity of Linc00152 was examined by RT-PCR amplified with separated cytoplasm RNA and
nuclear RNA in MGC803 and HGC-27 cells. HPRT was used as the control for cytoplasmic expression and U2 for nuclear. Data was presented
with mean ± SEM
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using ABI Prism 7900HT (Applied Biosystems, CA, USA)
according to the direction of the reagents. 2-ΔΔCT was
used to calculate the expression results obtained from ABI
7900HT. The mRNA expression of Linc00152 in human
tissues was normalized to 18S.
Western blot
The proteins were extracted as previously described
[16]. Equal amounts of cellular proteins were separated
by 10 % SDS-PAGE and visualized using an ECL kit
(Millipore, MA, USA).
Cell proliferation assay
The ability of cells proliferation was assayed using CCK-8
(Dojin Laboratories, Kumamoto, Japan) and EDU
(Millipore, Massachusetts, America) according to the
manufacturer’s instructions. The mock and infected
cells were seeded at a density of 1 × 104 cells/well in
96-well flat-bottom and respectively cultured for
CCK-8 and EDU assays according to the protocol
provided by manufacture. CCK8 was detected at 0,
24, 48 and 72 h. The EDU assay was performed after
the cells were cultured for 48 h.
In situ hybridization
Cells were fixed and permeablized using xylenes, ethanol
and protease to allow for biotin-labeled probe access.
Slides were boiled in pretreatment buffer for 15 min and
rinsed in water. Next, the probe was hybridized to the
lncRNA at 38 °C for 2 h. After this, the preamplifier was
hybridized to the target probes at 30 °C and amplified
with 6 cycles of hybridization followed by 2 washes.
Cells were counter-stained to visualize signal. Finally,
slides were DAB stained, dehydrated with 100 %
ethanol and xylene, and mounted in a xylene-based
mounting media.
The subcutaneous xenotransplantation model
Animal care and euthanasia were approved by the
Jiangsu University animal studies committee. Cells
(1 × 106) stably Linc00152 shRNA were subcutaneously
implanted into the bilateral axillas of 10 BALB/C nude
mice in each group. Tumors were measured every week
after implantation, and the volume of each tumor was cal-
culated (length × width2 × 0.5). All mice were sacrificed
5 weeks afterwards, and the xenografts were peeled off
subcutaneously.
RNA pull-down and RNA Immunoprecipitation (RIP)
The biotin-labeled lncRNA was transcribed with a Biotin
RNA Labeling Mix (Roche, CA, USA) and the T7 RNA
polymerase (Roche, CA, USA), treated with RNase-free
DNase I (Roche, CA, USA) and purified with an RNeasy
Mini Kit (Qiagen, Hilden, Germany). Protein extracted
from MGC803 was mixed with biotinylated RNA. 60 μL
washed streptavidin agarose beads (Invitrogen Life
Technologies, CA, USA) was then added to each binding
reaction and washed. The associated proteins were
resolved by SDS-PAGE, and specific bands were excised
and analyzed by mass spectrometry. Proteins in bands
were eluted and digested. Digests were analyzed by
Orbitrap Velos Pro LC/MS system (Thermo Scientific,
CA, USA). Data was analyzed by Proteome Discoverer
and the resulting peak lists were used for searching the
NCBI protein database with the Mascot search engine.
RIP assay was performed by using EZ-Magna RIP™
RNA-Binding Protein Immunoprecipitation Kit (Millipore,
MA, USA) according to the manufacturer’s instructions.
The EGFR antibody (ab2430) was used for RIP (Abcam,
Cambridge, UK). The co-precipitated RNAs were detected
by reverse transcription PCR and quantitative PCR. Total
RNAs (input controls) and IgG were assayed simultan-
eously to demonstrate that the detected signals were the
result of RNAs specifically binding to EGFR.
Table 1 Clinical relevance of Linc00152 and EGFR and patients
with gastric cancer
Linc00152 EGFR
Feather Low High P value Low High P value
All cases 36 36 36 36
Age 0.326 0.637
< 60 11 15 16 18
≥ 60 25 21 20 18
Gender 0.422 0.808
Male 28 25 23 22
Female 8 11 13 14
Differentiation grade 0.616 0.864
Well 18 15 16 18
Moderate 16 17 16 15
Poorly 2 4 4 3
Tumor size (cm) 0.004 0.003
≤ 5 cm 20 8 19 7
> 5 cm 16 28 17 29
Tumor Number 0.772 0.743
Solitary 28 29 30 31
Multiple 8 7 6 5
Metastasis 0.475 0.339
Yes 22 19 19 23
No 14 17 17 13
TNM stage 0.458 0.635
I-II 25 22 21 19
III-IV 11 14 15 17
P value in Bold indicated the significant analysis
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Statistical methods
All experiments were independently repeated at least
triplicate. Data were expressed as mean ± SEM. Differ-
ences between two independent groups were tested
with the student t test. All statistical analyses were
carried out using SPSS version 18.0 and presented
with Graphpad prism software. Pearson correlation
analysis was performed in calculating the correlation
between Linc00152 and EGFR, The results were con-
sidered to be statistically significant at P < 0.05.
Results
Cytoplasm located Linc00152 was increased in gastric cancer
We first detected the expression of Linc00152 in 72
patients’ tissues suffering from gastric cancer. The qRT-
PCR showed that the expression level of Linc00152 in
gastric cancer tissues was significantly increased, com-
pared with the corresponding adjacent non-normal tis-
sues (Fig. 1a). In addition, we employed eight human
gastric cancer cell lines to investigate the expression of
Linc00152. We found that MGC803 and HGC-27 was
expressed with a high abundance (Fig. 1b). We then de-
tected the location of Linc00152 through a RT-PCR
amplified with separated cytoplasm RNA and nuclear
RNA in MGC803 and HGC-27 cells. We found that
Linc00152 mainly located in the cytoplasm (Fig. 1c).
According to the collected clinical information, the
relevance between Linc00152 expression in gastric
cancer tissues and clinicopathological characteristics is
presented in Table 1. Here we found significant correl-
ation with tumor size instead of tumor number, differen-
tiation grade, TNM stage or metastasis.
Fig. 2 Decreased level of Linc00152 suppressed cell proliferation in vitro. a Expression level of Linc00152 in MGC803 and HGC-27 cells treated
with shRNA. b The CCK8 assay detected in different time points including 0, 24, 48 and 72 h showed a decreased level of Linc00152 inhibited the
growth of cell lines. Absorbance at 450 nm was presented as the mean ± SEM. c The EDU assay confirmed the functional role of Linc00152 in cell
proliferation. d The integral optical density value of cells treated with control plasmids was normalized to 100 %. All experiments were performed
in triplicate and presented as the mean ± SEM. *indicates P < 0.05 while **indicated P < 0.01
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Linc00152 promoted cell proliferation in vitro
The obvious correlation between Linc00152 expression
and clinicopathological characteristics demonstrated that
Linc00152 might play a vital role in the tumor growth of
gastric cancer. We next selected MGC803 and HGC-27
to investigate the effects of shRNA-mediated knockdown
of Linc00152 on cell proliferation. Two lncRNA-specific
shRNAs were evaluated of their knockdown efficiency
(Fig. 2a). We finally chose Lv-shRNA-1 in the following
experiment due to a higher knockdown efficiency. CCK8
assay detected in different time point indicated that
down-regulation of Linc00152 inhibited proliferation in
both MGC803 and HGC-27 cells (Fig. 2b). Further EDU
assay confirmed the results which also revealed that the
decreased level of Linc00152 could cause a suppression
of cell proliferation in both MGC803 and HGC-27 cells
(Fig. 2c and d).
Linc00152 induced a promotion of tumor growth in vivo
In order to confirm the effects of Linc00152 on
tumorigenesis in vivo, we conducted a nude mice
xenograft experiment by subcutaneously injected with
MGC803 and HGC-27 cells stably knocked down for
Linc00152 or a mock vector into flanks of 4–6 week-
old BALB/C nude mice. As presented in Fig. 3a and c, we
observed that tumor growth was significantly decreased
compared with the mock. We also calculated the
tumor volume nearly every three days, the growth
curve presented in Fig. 3b and d demonstrated a re-
markable suppression affection of cells treated with
Linc00152 shRNA.
Linc00152 constitutive activated PI3K/AKT signaling by
direct binding with EGFR
Linc00152 was reported to be up-regulated in multiple can-
cers and may play important roles in post-transcriptional
regulation in cancer [17]. However, the specific signal path-
way involved by the abnormal expression of Linc00152 still
remained unknown. The RNA pull-down assay was applied
to explore the potential binding protein. As presented in
Fig. 4a, the protein located around 140 kDa was developed
comparing with the antisense of Linc00152. Further mass
spectrometry identification indicated that EGFR was the
captured protein by Linc00152 (Fig. 4b). RNA immunopre-
cipitation (RIP) verified the specificity of this interaction,
suggesting that Linc00152 could bind with EGFR and
might regulate EGFR activity (Fig. 4c and d).
We next analyzed the mRNA and protein expression
of EGFR in the tissues samples of patients mentioned
above. We found a significant increased level of EGFR
and p-EGFR in gastric cancers (Fig. 5a and b). We
further divided the cancer tissues into Linc00152 high
group and low group by using the median of Linc00152
expression as cutoff. Both the mRNA and protein inves-
tigation demonstrated that an elevated level of EGFR
and p-EGFR accompany with Linc00152 (Fig. 5c and d).
Pearson correlation analysis also presented a positive
correlation between the expression of Linc00152 and
EGFR (Fig. 5e). The expression of EGFR was also associ-
ated with tumor size as presented in Table 1. The trad-
itional EGFR signaling pathway was detected by using
samples obtained both in cells lines and xenograft tumor
in mice. The inhibition of p-EGFR, p-AKT or p-PI3K
was obtained in cells treated with Linc00152 shRNA
Fig. 3 Down-regulation of Linc00152 suppressed tumor growth in vivo. a, c Tumor tissues obtained from Xenograft model in nude mice
(at least 10 mice in each group). a panel presented MGC803 mice while (c) indicated HGC-27 cell lines. b, d Mice with established
tumors were measured almost every three days and was presented in the right panel. b panel presented MGC803 mice while (d)
indicated HGC-27 cell lines. *indicated p < 0.05
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which indicating that Linc00152 might cause a constitu-
tive activation of EGFR signaling (Fig. 5f ).
Discussion
In our present study, we found that the average level of
Linc00152 in GC tissues was significantly higher than
those in corresponding non-tumor tissues. The high
expression level of Linc00152 in GC patients was associ-
ated with tumor size. Similarly, it has been revealed that
Linc00152 was up-regulated in liver caners and might be
applied as a biomarker for the diagnosis. Our results
confirmed the upregulation of Linc00152 in GC patients
of our cohort. Based on the clinical characteristic ana-
lysis, we found that Linc00152 was highly associated
with tumor size of GC patients instead of the metastasis
or differentiation.
Although Linc00152 have been studied in a variety of
physiological and pathological processes, such as liver
cancer and pancreatic cancer [18], the possible role and
associated molecular mechanism of Linc00152 in human
Fig. 4 EGFR was identified as a binding target of Linc00152. a RNA pull-down experiment with MGC803 extract in different groups. The left two
bands indicated Linc00152 wide type while the right two bands presented the antisense of Linc00152. b Mass spectrometry identification of target
band of EGFR. The secondary ion mass spectrometry with the peptide sequence labeled was presented. c, d RIP assay was performed using EGFR
antibody and was validated by agarose electrophoresis by using different primer. The band from the top to bottom presented DNA marker, RNA
extracted with EGFR antibody treating, input (regard as a positive control) and IgG (negative control), respectively. Fold change enrichment was
calculated comparing with the input in panel d. Data was presented with mean ± SEM
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gastric cancer remains to be clarified. Our results
showed that Linc00152 knockdown could significantly
inhibit gastric cancer cell proliferation both in vitro and
in vivo. The RNA pull-down assay and RIP both con-
firmed that Linc00152 might be directly bind with EGFR
which caused a constitutive activation of EGFR. LncRNA
has been reported as an enhancer factor or suppres-
sion factor with specific protein through direct bind-
ing, for example, lncRNA-Dreh could combine with
the intermediate filament protein vimentin and re-
press its expression [19].
EGFR belongs to the family of receptor tyrosine kinases
(RTK) ErbB, which consisting of HER1/EGFR/ErbB1,
HER2/Neu/ErbB2, HER3/ErbB3 and HER4/ErbB4 [20].
EGFR is overexpressed in various cancers, including non-
small cell lung cancer, colorectal cancer, pancreatic cancer,
esophagogastric cancer and gastric cancer as well [21].
EGFR is recognized as oncogenic driver in tumorigenesis
Fig. 5 Linc00152 highly correlated with EGFR and constitutively activated PI3K/AKT signaling. a Different expression of EGFR mRNA in 72 pairs
tissues from gastric cancer patients. b The protein expression level of EGFR in patients with gastric cancer. c, d Patients was divided into
Linc00152high and Linc00152low groups based on the median of Linc00152 expression. The mRNA (panel c) and protein expression (panel d)
of EGFR were compared in the two groups. e Pearson analysis was performed in calculating the correlation of Linc00152 and EGFR with
log-transformed data. f The activation of PI3K/AKT signaling was measured by detecting the p-EGFR, p-PI3K and p-AKT in both cells line and
tumors from Xenograft model. Data was presented with mean ± SEM
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and a target for cancer therapies. Researchers has identi-
fied that overexpression of EGFR could increase the prolif-
eration of tumor cell through the PI3K-AKT signaling
pathway and it is likely to be an independent predictor of
poor prognosis [22]. So it is of great value to determine
EGFR status to interpret future clinical trials properly
using EGFR targeted agents.
Conclusions
Our findings demonstrated the promotion effect of
Linc00152 in vivo and vitro. Additionally, our results indi-
cated that EGFR, contribute to the downstream regulation
of Linc00152 in gastric cancer which may serve as poten-
tial targets for therapy in the future.
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